Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy
- PMID: 15671132
- DOI: 10.1177/0269881105048900
Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy
Abstract
This review of chronic tolerance to MDMA (3,4-methylenedioxymetamphetamine) covers the empirical data on dosage escalation, reduced subjective efficacy and bingeing in recreational Ecstasy users. Novice users generally take a single Ecstasy tablet, regular users typically take 2-3 tablets, whereas the most experienced users may take 10-25 tablets in a single session. Reduced subjective efficacy following repeated usage is typically described, with many users subjectively reporting the development of tolerance. Intensive self-administration or bingeing is often noted by experienced users. This can comprise 'stacking' on several tablets together, and 'boosting' on successive doses over an extended period. Some experienced users snort Ecstasy powder nasally, whereas a small minority inject MDMA. Chronic tolerance and bingeing are statistically linked to higher rates of drug-related psychobiological problems. In terms of underlying mechanisms, neuroadaptive processes are certainly involved, but there is a paucity of evidence on hepatic and behavioural mechanisms. Further studies specifically designed to investigate chronic tolerance, involving low intermittent dose regimens, are required. Most animal research has involved intensive MDMA dosing regimens designed to engender serotonergic neurotoxicity, and this may comprise another underlying mechanism. If distal serotonin axon terminal loss was also developing in recreational users, it may help to explain why reducing subjective efficacy, dosage escalation and increasing psychobiological problems often develop in parallel. In conclusion, there is extensive evidence for chronic pharmacodynamic tolerance to recreational Ecstasy/MDMA, but the underlying mechanisms are currently unclear. Several traditional processes are probably involved, but one of the possible causes is a novel mechanism largely unique to the ring substituted amphetamine derivatives, namely serotonergic neurotoxicity.
Similar articles
-
MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress.J Psychopharmacol. 2006 Mar;20(2):147-63. doi: 10.1177/0269881106063268. J Psychopharmacol. 2006. PMID: 16510474 Review.
-
Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research.Hum Psychopharmacol. 2001 Dec;16(8):557-577. doi: 10.1002/hup.351. Hum Psychopharmacol. 2001. PMID: 12404536
-
Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a WWW study.Addict Behav. 2004 Jun;29(4):743-52. doi: 10.1016/j.addbeh.2004.02.022. Addict Behav. 2004. PMID: 15135556
-
Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.J Psychopharmacol. 2006 Mar;20(2):211-25. doi: 10.1177/0269881106059486. J Psychopharmacol. 2006. PMID: 16510479 Review.
-
Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users.Hum Psychopharmacol. 2002 Aug;17(6):309-12. doi: 10.1002/hup.415. Hum Psychopharmacol. 2002. PMID: 12404677
Cited by
-
Cannabis and Ecstasy/MDMA (3,4-methylenedioxymethamphetamine): an analysis of their neuropsychobiological interactions in recreational users.J Neural Transm (Vienna). 2007;114(8):959-68. doi: 10.1007/s00702-007-0715-7. Epub 2007 May 24. J Neural Transm (Vienna). 2007. PMID: 17520319 Review.
-
Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance.Psychopharmacology (Berl). 2008 Oct;200(3):439-50. doi: 10.1007/s00213-008-1218-4. Epub 2008 Jul 27. Psychopharmacology (Berl). 2008. PMID: 18661256 Free PMC article.
-
Reinforcing effects of methylenedioxy amphetamine congeners in rhesus monkeys: are intravenous self-administration experiments relevant to MDMA neurotoxicity?Psychopharmacology (Berl). 2007 Jan;189(4):471-82. doi: 10.1007/s00213-006-0320-8. Epub 2006 Mar 23. Psychopharmacology (Berl). 2007. PMID: 16555062 Review.
-
Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study.Brain. 2010 Jun;133(Pt 6):1779-97. doi: 10.1093/brain/awq103. Epub 2010 May 17. Brain. 2010. PMID: 20483717 Free PMC article.
-
Ecstasy, molly, MDMA: What health practitioners need to know about this common recreational drug.Dis Mon. 2025 Mar;71(3):101851. doi: 10.1016/j.disamonth.2024.101851. Epub 2025 Jan 14. Dis Mon. 2025. PMID: 39814637 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical